The aim of this study is to determine the Pharmacokinetics/Pharmacodynamics(PK/PD) of tigecycline in critical ill patients undergoing continuous renal replacement therapy（CRRT）and examine whether the dosage needs adjustment. The study will observe two groups of patients respectively and compare the difference between them. Patients who need to receive CRRT when treat with high-dose tigecycline will be collected in Group CRRT. Patients who treat with high-dose tigecycline only will be collected in Group non-CRRT.
Study Type
OBSERVATIONAL
Enrollment
20
Patients who have the definitive diagnosis to treat with tigecycline for bacterial infection will be started on tigecycline with a loading dose 200mg IV followed by 100mg IV every 12h.
Zhujiang Hospital,Southern Medical University
Guangzhou, Guangdong, China
RECRUITINGTigecycline Steady State Plasma Concentrations
Steady State Plasma Concentration(Css) in blood
Time frame: Day 1-3
Peak Plasma Concentration(Cmax) of Tigecycline in blood
Time frame: Day 1-3
Trough Plasma Concentration(Cmin) of Tigecycline in blood
Time frame: Day 1-3
Area Under the Plasma Concentration versus Time Curve(AUC)
Time frame: Day 1-3
Minimal Inhibitory Concentration(MIC)
Time frame: Day 1-3
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.